CA2164260C - Methode de ciblage pour medicaments et agents therapeutiques - Google Patents

Methode de ciblage pour medicaments et agents therapeutiques Download PDF

Info

Publication number: CA2164260C
Authority: CA; Canada
Prior art keywords: agent; liver; hyaluronic acid; amount; effective
Prior art date: 1995-12-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002164260A

Other languages

English (en)

Other versions

CA2164260A1 (fr

Inventor

Stefan Gustafson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Jagotec AG

Original Assignee

Jagotec AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-01

Filing date

1995-12-01

Publication date

2001-10-09

1995-12-01 Priority to CA002164260A priority Critical patent/CA2164260C/fr

1995-12-01 Application filed by Jagotec AG filed Critical Jagotec AG

1996-11-29 Priority to ZA9610039A priority patent/ZA9610039B/xx

1996-11-29 Priority to EP96939774A priority patent/EP0869798A1/fr

1996-11-29 Priority to BR9611671-4A priority patent/BR9611671A/pt

1996-11-29 Priority to JP09520818A priority patent/JP2000513707A/ja

1996-11-29 Priority to HU9901935A priority patent/HUP9901935A3/hu

1996-11-29 Priority to PCT/CA1996/000793 priority patent/WO1997020564A1/fr

1996-11-29 Priority to AU76878/96A priority patent/AU727001B2/en

1996-11-29 Priority to IL12474796A priority patent/IL124647A0/xx

1996-11-29 Priority to KR1019980703904A priority patent/KR19990071628A/ko

1996-11-29 Priority to PL96326970A priority patent/PL326970A1/xx

1997-06-02 Publication of CA2164260A1 publication Critical patent/CA2164260A1/fr

1998-05-28 Priority to NO982441A priority patent/NO982441L/no

1998-06-01 Priority to MX9804343A priority patent/MX9804343A/es

2001-10-09 Application granted granted Critical

2001-10-09 Publication of CA2164260C publication Critical patent/CA2164260C/fr

2015-12-01 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000003814 drug Substances 0.000 title claims abstract description 170
229940124597 therapeutic agent Drugs 0.000 title claims abstract description 83
229940079593 drug Drugs 0.000 title claims description 15
230000008685 targeting Effects 0.000 title description 9
239000003795 chemical substances by application Substances 0.000 claims abstract description 200
210000004185 liver Anatomy 0.000 claims abstract description 127
102000005962 receptors Human genes 0.000 claims abstract description 36
108020003175 receptors Proteins 0.000 claims abstract description 36
230000002829 reductive effect Effects 0.000 claims abstract description 25
201000010099 disease Diseases 0.000 claims abstract description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
230000001105 regulatory effect Effects 0.000 claims abstract description 17
231100000252 nontoxic Toxicity 0.000 claims abstract description 16
230000003000 nontoxic effect Effects 0.000 claims abstract description 16
102000014452 scavenger receptors Human genes 0.000 claims abstract description 15
108010078070 scavenger receptors Proteins 0.000 claims abstract description 15
230000002222 downregulating effect Effects 0.000 claims abstract description 9
229920002674 hyaluronan Polymers 0.000 claims description 167
229960003160 hyaluronic acid Drugs 0.000 claims description 119
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 117
229920001287 Chondroitin sulfate Polymers 0.000 claims description 83
230000032258 transport Effects 0.000 claims description 40
206010028980 Neoplasm Diseases 0.000 claims description 37
150000003839 salts Chemical class 0.000 claims description 27
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 23
229920002683 Glycosaminoglycan Polymers 0.000 claims description 22
230000037396 body weight Effects 0.000 claims description 22
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 18
229920000669 heparin Polymers 0.000 claims description 18
229960002897 heparin Drugs 0.000 claims description 18
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 17
229910021653 sulphate ion Inorganic materials 0.000 claims description 17
229920000288 Keratan sulfate Polymers 0.000 claims description 11
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 11
108010022164 acetyl-LDL Proteins 0.000 claims description 10
229940127089 cytotoxic agent Drugs 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 10
FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 claims description 9
229920000045 Dermatan sulfate Polymers 0.000 claims description 9
239000002254 cytotoxic agent Substances 0.000 claims description 7
231100000599 cytotoxic agent Toxicity 0.000 claims description 7
201000011510 cancer Diseases 0.000 claims description 4
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
206010027476 Metastases Diseases 0.000 claims description 3
210000003722 extracellular fluid Anatomy 0.000 claims description 3
231100000334 hepatotoxic Toxicity 0.000 claims description 3
210000002751 lymph Anatomy 0.000 claims description 3
238000000034 method Methods 0.000 abstract description 12
229940099552 hyaluronan Drugs 0.000 description 48
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 47
WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 28
229940014041 hyaluronate Drugs 0.000 description 28
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 22
229920002385 Sodium hyaluronate Polymers 0.000 description 16
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 16
229940010747 sodium hyaluronate Drugs 0.000 description 16
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 16
230000000694 effects Effects 0.000 description 15
210000001519 tissue Anatomy 0.000 description 13
241000700159 Rattus Species 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
229960000905 indomethacin Drugs 0.000 description 8
239000002246 antineoplastic agent Substances 0.000 description 7
210000002540 macrophage Anatomy 0.000 description 7
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
229930003268 Vitamin C Natural products 0.000 description 6
239000000463 material Substances 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
239000000243 solution Substances 0.000 description 6
235000019154 vitamin C Nutrition 0.000 description 6
239000011718 vitamin C Substances 0.000 description 6
229960005070 ascorbic acid Drugs 0.000 description 5
235000010323 ascorbic acid Nutrition 0.000 description 5
239000011668 ascorbic acid Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
229920002307 Dextran Polymers 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
239000012634 fragment Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
210000005229 liver cell Anatomy 0.000 description 4
230000001394 metastastic effect Effects 0.000 description 4
206010061289 metastatic neoplasm Diseases 0.000 description 4
229960000485 methotrexate Drugs 0.000 description 4
230000001613 neoplastic effect Effects 0.000 description 4
VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
230000003637 steroidlike Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
239000000061 acid fraction Substances 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940124599 anti-inflammatory drug Drugs 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
229940041181 antineoplastic drug Drugs 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000008033 biological extinction Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
229960004316 cisplatin Drugs 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
229960003883 furosemide Drugs 0.000 description 3
230000006872 improvement Effects 0.000 description 3
229960002009 naproxen Drugs 0.000 description 3
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
238000002203 pretreatment Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
150000003180 prostaglandins Chemical class 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000004044 response Effects 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 2
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
108010036941 Cyclosporins Proteins 0.000 description 2
241000792859 Enema Species 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
108010013214 Hyaluronan Receptors Proteins 0.000 description 2
102000018866 Hyaluronan Receptors Human genes 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
208000010159 IgA glomerulonephritis Diseases 0.000 description 2
206010021263 IgA nephropathy Diseases 0.000 description 2
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 2
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
102000023732 binding proteins Human genes 0.000 description 2
108091008324 binding proteins Proteins 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
229940124630 bronchodilator Drugs 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
229960001927 cetylpyridinium chloride Drugs 0.000 description 2
239000006071 cream Substances 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
239000007920 enema Substances 0.000 description 2
229940095399 enema Drugs 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
229960002442 glucosamine Drugs 0.000 description 2
229940097043 glucuronic acid Drugs 0.000 description 2
230000003779 hair growth Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
201000006747 infectious mononucleosis Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
229960004752 ketorolac Drugs 0.000 description 2
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000003908 liver function Effects 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
-1 methyl CCNU Chemical compound 0.000 description 2
229960003632 minoxidil Drugs 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229950006780 n-acetylglucosamine Drugs 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
229940087419 nonoxynol-9 Drugs 0.000 description 2
229920004918 nonoxynol-9 Polymers 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
230000009325 pulmonary function Effects 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
230000008961 swelling Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
230000002792 vascular Effects 0.000 description 2
AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
BLXVTZPGEOGTGG-UHFFFAOYSA-N 2-[2-(4-nonylphenoxy)ethoxy]ethanol Chemical compound CCCCCCCCCC1=CC=C(OCCOCCO)C=C1 BLXVTZPGEOGTGG-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
241000282709 Aotus trivirgatus Species 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
102100032912 CD44 antigen Human genes 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
102100021906 Cyclin-O Human genes 0.000 description 1
229940123457 Free radical scavenger Drugs 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
241001071864 Lethrinus laticaudis Species 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
206010061137 Ocular toxicity Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
206010044245 Toxic optic neuropathy Diseases 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
238000003287 bathing Methods 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
229940092705 beclomethasone Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
208000020670 canker sore Diseases 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003161 choroid Anatomy 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
229920001577 copolymer Chemical class 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
210000000695 crystalline len Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
230000009429 distress Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
210000002767 hepatic artery Anatomy 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940028843 inosinic acid Drugs 0.000 description 1
239000004245 inosinic acid Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000000554 iris Anatomy 0.000 description 1
229960004384 ketorolac tromethamine Drugs 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
230000004899 motility Effects 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
231100000327 ocular toxicity Toxicity 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000009781 safety test method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA002164260A 1995-12-01 1995-12-01 Methode de ciblage pour medicaments et agents therapeutiques Expired - Lifetime CA2164260C (fr)

Priority Applications (13)

Application Number	Priority Date	Filing Date	Title
CA002164260A CA2164260C (fr)	1995-12-01	1995-12-01	Methode de ciblage pour medicaments et agents therapeutiques
PL96326970A PL326970A1 (en)	1995-12-01	1996-11-29	Orientation of dosage of drugs and therapeutic agents as well as othe glykozaminoglykanes (gags)
BR9611671-4A BR9611671A (pt)	1995-12-01	1996-11-29	Método de alvejamento de dosagens de medicamentos e de agentes terapêuticos e de outros glicosaminoglicanos (gags) para tratar de uma doença ou condição em um ser humano.
JP09520818A JP2000513707A (ja)	1995-12-01	1996-11-29	投与薬剤の目標化、治療薬および他のグリコサミノグリカン（ｇａｇｓ）
HU9901935A HUP9901935A3 (en)	1995-12-01	1996-11-29	Dosage kit for targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags)
PCT/CA1996/000793 WO1997020564A1 (fr)	1995-12-01	1996-11-29	Ciblage de dosages d'agents medicinaux et therapeutiques et d'autres glycosaminoglycans (gags)
ZA9610039A ZA9610039B (en)	1995-12-01	1996-11-29	Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags)
IL12474796A IL124647A0 (en)	1995-12-01	1996-11-29	Targeting of dosages of medicine and therapeutic agents and other glycos aminoglycans (gags)
KR1019980703904A KR19990071628A (ko)	1995-12-01	1996-11-29	약물, 치료요법제 및 다른 글리코자미노글리칸(gags)약량을 표적화시키는 방법
EP96939774A EP0869798A1 (fr)	1995-12-01	1996-11-29	Ciblage de dosages d'agents medicinaux et therapeutiques et d'autres glycosaminoglycans (gags)
AU76878/96A AU727001B2 (en)	1995-12-01	1996-11-29	Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (GAGS)
NO982441A NO982441L (no)	1995-12-01	1998-05-28	MÕls°king av medisindoser, terapeutiske midler og andre glycosaminoglykaner (GAGS)
MX9804343A MX9804343A (es)	1995-12-01	1998-06-01	Aplicacion dirigida de dosificaciones de agentes medicinales y terapeuticos y otros glicosaminoglicanos (gags).

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002164260A CA2164260C (fr)	1995-12-01	1995-12-01	Methode de ciblage pour medicaments et agents therapeutiques

Publications (2)

Publication Number	Publication Date
CA2164260A1 CA2164260A1 (fr)	1997-06-02
CA2164260C true CA2164260C (fr)	2001-10-09

Family

ID=4157078

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002164260A Expired - Lifetime CA2164260C (fr)	1995-12-01	1995-12-01	Methode de ciblage pour medicaments et agents therapeutiques

Country Status (2)

Country	Link
CA (1)	CA2164260C (fr)
ZA (1)	ZA9610039B (fr)

1995
- 1995-12-01 CA CA002164260A patent/CA2164260C/fr not_active Expired - Lifetime
1996
- 1996-11-29 ZA ZA9610039A patent/ZA9610039B/xx unknown

Also Published As

Publication number	Publication date
ZA9610039B (en)	1997-06-20
CA2164260A1 (fr)	1997-06-02

Legal Events

Date	Code	Title	Description
1995-12-01	EEER	Examination request
2016-02-02	MKEX	Expiry	Effective date: 20151201

Publication	Publication Date	Title
EP0656213B1 (fr)	2002-11-13	Utilisation combinee de l'acide hyaluronique et d'agents therapeutiques pour ameliorer l'effet therapeutique
US5614506A (en)	1997-03-25	Use of hyaluronic acid and forms to prevent arterial restenosis
CA2122519C (fr)	2001-02-20	Traitement du cancer et prevention des metastases
WO1996006622A1 (fr)	1996-03-07	Acide hyaluronique et derives destines a la modulation de l'activite cellulaire
US5674857A (en)	1997-10-07	Use of hyaluronic acid to repair ischemia reperfusion damage
US5834444A (en)	1998-11-10	Hyaluronic acid and salts thereof inhibit arterial restenosis
CA2175282A1 (fr)	1997-10-30	Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
US5817644A (en)	1998-10-06	Targeting of dosages of medicine and therapeutic agents
EP0874624B1 (fr)	2003-12-03	Ligands des recepteurs a l'acide hyaluronique et leur utilisation dans le traitement des tumeurs et de la restenose
AU727001B2 (en)	2000-11-30	Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (GAGS)
AP448A (en)	1996-01-18	Use of hyaluronic acid and forms to prevent arterial restenosis.
CA2173037A1 (fr)	1997-09-30	Transport de medicaments et d'agents therapeutiques jusqu'a un site donne de l'organisme
CA2166154A1 (fr)	1997-06-28	Agents liants et utilisation correspondante
CA2131130A1 (fr)	1996-03-01	Modulation de l'activite cellulaire
CA2156013A1 (fr)	1997-02-15	Modulation de l'activite cellulaire
CA2145605A1 (fr)	1996-09-28	Modulation de l'activite cellulaire
HK1005985B (en)	2003-02-14	Combined use of hyaluronic acid and therapeutic agents to improve the therapeutic effect
CA2194750A1 (fr)	1998-07-09	Methodes pour l'augmentation des quantites d'hyaluronane dans l'organisme humain
CA2193940A1 (fr)	1998-06-24	Methodes pour augmenter les quantites d'hyaluronan dans l'organisme humain
HK1005984A (en)	1999-02-05	The use of hyaluronic acid to repair ischemia reperfusion damage
Mateu et al.	1994	Ifosfamide extravasation